# MIRA Pharmaceuticals Reports MIRA-55 Avoids CNS Side Effects > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/synthetic-cannabinoids-cns-side-effects-mira-55-research/ > **Published:** 2026-03-24T12:01:49-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:41:01-04:00 > **Clinical Summary:** Explore synthetic cannabinoids CNS side effects and how MIRA-55 shows promise in avoiding these issues in preclinical studies. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Synthetic CannabinoidsCns Side Effects[Drug Development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/)Cb1 AntagonistsPharmaceutical Research Why This Matters Early preclinical data suggests MIRA-55, a synthetic cannabinoid compound, may avoid the central nervous system side effects that have limited clinical adoption of THC and previous CB1 antagonists like rimonabant. If validated in human trials, this could represent a significant advancement in developing therapeutically useful cannabinoid medicines without psychoactive or psychiatric adverse effects. Clinical Summary MIRA Pharmaceuticals reports preclinical studies showing their synthetic cannabinoid compound MIRA-55 does not produce the CNS side effects associated with THC (euphoria, cognitive impairment) or rimonabant (depression, anxiety, suicidal ideation). Rimonabant was a CB1 receptor antagonist withdrawn from markets due to serious psychiatric adverse events. The mechanism by which MIRA-55 achieves therapeutic effects while avoiding these CNS complications has not been detailed in available information. These are preclinical findings requiring validation in human clinical trials. Dr. Caplan’s Take “This is exactly the kind of pharmacological refinement the field needs — compounds that can harness therapeutic cannabinoid pathways without the limiting side effects. However, preclinical promises don’t always translate to human reality, and we’ve seen this movie before with other ‘cleaner’ cannabinoid compounds.” Clinical Perspective 🧠 Clinicians should monitor MIRA-55’s progression through human trials, as CNS-sparing cannabinoid therapeutics could expand treatment options for patients who cannot tolerate traditional cannabis medicines. The key will be whether human studies confirm both efficacy and the absence of psychiatric side effects that plagued rimonabant. Until clinical data emerges, this remains a research development rather than a practice-changing advance. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20MIRA%20Pharmaceuticals%20Reports%20Mira-55%20Shows%20No%20THC-%20or%20Rimonabant-Associated%20CNS%20...%20%40drcaplan&url=https%3A//www.providencejournal.com/press-release/story/46694/mira-pharmaceuticals-reports-mira-55-shows-no-thc-or-rimonabant-associated-cns-side-effects-in-preclinical-studies/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.providencejournal.com/press-release/story/46694/mira-pharmaceuticals-reports-mira-55-shows-no-thc-or-rimonabant-associated-cns-side-effects-in-preclinical-studies/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20MIRA%20Pharmaceuticals%20Reports%20Mira-55%20Shows%20No%20THC-%20or%20Rimonabant-Associated%20CNS%20...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.providencejournal.com/press-release/story/46694/mira-pharmaceuticals-reports-mira-55-shows-no-thc-or-rimonabant-associated-cns-side-effects-in-preclinical-studies/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.providencejournal.com/press-release/story/46694/mira-pharmaceuticals-reports-mira-55-shows-no-thc-or-rimonabant-associated-cns-side-effects-in-preclinical-studies/](https://www.providencejournal.com/press-release/story/46694/mira-pharmaceuticals-reports-mira-55-shows-no-thc-or-rimonabant-associated-cns-side-effects-in-preclinical-studies/) Table of Contents - [FAQ](#FAQ)[What are synthetic cannabinoids?](#What_are_synthetic_cannabinoids) - [What are CB1 antagonists and how do they work?](#What_are_CB1_antagonists_and_how_do_they_work) - [What CNS side effects are associated with these compounds?](#What_CNS_side_effects_are_associated_with_these_compounds) - [Why is this considered clinically relevant for healthcare providers?](#Why_is_this_considered_clinically_relevant_for_healthcare_providers) - [What does this mean for drug development in the cannabis field?](#What_does_this_mean_for_drug_development_in_the_cannabis_field) - [Related](#Related) ## FAQ #### What are synthetic cannabinoids? Synthetic cannabinoids are artificially created chemical compounds that mimic the effects of natural cannabinoids found in cannabis. These laboratory-made substances are designed to interact with the same brain receptors as THC but can have unpredictable and potentially dangerous effects. #### What are CB1 antagonists and how do they work? CB1 antagonists are drugs that block the CB1 [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/) in the brain and nervous system. By preventing cannabinoids from binding to these receptors, CB1 antagonists can counteract or prevent the psychoactive effects of cannabis and synthetic cannabinoids. #### What CNS side effects are associated with these compounds? Central nervous system (CNS) side effects can include altered mental state, seizures, psychosis, and impaired [cognitive function](https://cedclinic.com/reverse-cholesterol-transport-function-cannabis-users/). These effects can be particularly severe and unpredictable with synthetic cannabinoids compared to natural cannabis. #### Why is this considered clinically relevant for healthcare providers? Healthcare providers need to stay informed about emerging synthetic cannabinoids and their antagonists due to increasing patient presentations and potential therapeutic applications. Understanding these compounds is crucial for proper diagnosis, treatment, and management of cannabis-related medical issues. #### What does this mean for drug development in the cannabis field? This research represents ongoing efforts to develop both therapeutic cannabinoid compounds and their antidotes. Such developments could lead to safer [medical cannabis products](https://cedclinic.com/cannabis-infused-products-skin-diy-topical-recipes/) and better treatments for cannabinoid overdoses or adverse reactions. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS …”, “url”: “https://www.providencejournal.com/press-release/story/46694/mira-pharmaceuticals-reports-mira-55-shows-no-thc-or-rimonabant-associated-cns-side-effects-in-preclinical-studies/”, “datePublished”: “2026-03-23T18:13:48Z”, “about”: “mira pharmaceuticals reports mira 55 shows”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Mira-55 Shows No THC- or Rimonabant-Linked CNS Side Effects in Preclinical Tests](https://cedclinic.com/cb1-receptor-modulation-mira-55-no-cns-side-effects/) Detailed preclinical findings on MIRA-55’s lack of CNS side effects compared to THC and rimonabant. [Read More](https://cedclinic.com/cb1-receptor-modulation-mira-55-no-cns-side-effects/) [Researchers Discover Cannabis Compounds That May Fight Obesity Without the High](https://cedclinic.com/non-intoxicating-cannabinoid-compounds-fight-obesity/) Explore new [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) with therapeutic potential and minimal psychoactive effects. [Explore Research](https://cedclinic.com/non-intoxicating-cannabinoid-compounds-fight-obesity/) [Study Finds Cannabis Compounds May Help Reduce Fatty Liver Disease](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) Emerging evidence on [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) offering benefits for liver health without CNS side effects. [Learn More](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).